Site icon Market Globalist

Here’s how Jaguar Health, Inc. (JAGX) plummeted in the premarket today

MTTR

MTTR

Jaguar Health, Inc. (NASDAQ:JAGX) shares dipped -22.63% to $0.82 in the premarket session ‎after the report that the Firm has reached an agreement with a secured lender a non-‎dilutive royalty funding deal.In the agreement, Jaguar will sell a royalty interest to the ‎Lender for an aggregate purchase price of $6 million, entitling the Lender to obtain 2.0x the ‎royalty purchase price of Mytesi and Lechlemer’s potential royalties and others upwards of ‎‎$6 million.‎

Get the hottest stocks to trade every day ‎before the market opens 100% ‎free. Click here now. 

‎Jaguar plans to use the proceeds to finance the Company’s research pipeline-related ‎regulatory operations, including ongoing funding patient registration for the cornerstone ‎phase 3 trial of crofelemer for diarrhea prophylaxis in adult cancer patients undergoing ‎targeted therapy launched last October by the wholly-owned subsidiary of the Company, ‎Napo Pharmaceuticals, Inc. (Napo). This $6 million royalty funding deal follows an earlier $6 ‎million royalty transaction with a Lender partner concluded in October 2020.‎

Read More

Moreover, we reported yesterday that Jaguar Health (JAGX) announced the results of the ‎special meeting of Jaguar stockholders ‎held on December 9, 2020. ‎

Exit mobile version